Studie - Thyroid Gland Disorders – Pipeline Review, H1 2012

Thyroid Gland Disorders — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Thyroid Gland Disorders - Pipeline Review, H1 2012', provides an overview of the Thyroid Gland Disorders therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Gland Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Gland Disorders. 'Thyroid Gland Disorders - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Thyroid Gland Disorders.
- A review of the Thyroid Gland Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thyroid Gland Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Thyroid Gland Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Thyroid Gland Disorders pipeline depth and focus of Thyroid Gland Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Thyroid Gland Disorders Overview 5

Therapeutics Development 6

An Overview of Pipeline Products for Thyroid Gland Disorders 6

Thyroid Gland Disorders Therapeutics under Investigation by Universities/Institutes 8

Mid Clinical Stage Products 9

Comparative Analysis 9

Thyroid Gland Disorders Therapeutics — Products under Investigation by Universities/Institutes 10

Thyroid Gland Disorders — Therapeutics Assessment 11

Assessment by Monotherapy Products 11

Assessment by Route of Administration 12

Assessment by Molecule Type 14

Drug Profiles 16

Thyrotropin Releasing Hormone - Drug Profile 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Thyroid Gland Disorders — Product Development Milestones 17

Featured News & Press Releases 17

Mar 10, 2010: Lithera Completes Phase I Clinical Trial Of LIPO-102 17

Appendix 18

Methodology 18

Coverage 18

Secondary Research 18

Primary Research 18

Expert Panel Validation 18

Contact Us 19

Disclaimer 19





List of Tables

Number of Products Under Development for Thyroid Gland Disorders, H1 2012 6

Products under Development for Thyroid Gland Disorders — Comparative Analysis, H1 2012 7

Number of Products under Investigation by Universities/Institutes, H1 2012 8

Comparative Analysis by Mid Clinical Stage Development, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Assessment by Monotherapy Products, H1 2012 11

Assessment by Stage and Route of Administration, H1 2012 13

Assessment by Stage and Molecule Type, H1 2012 15





List of Figures

Number of Products under Development for Thyroid Gland Disorders, H1 2012 6

Products under Development for Thyroid Gland Disorders — Comparative Analysis, H1 2012 7

Products under Investigation by Universities/Institutes, H1 2012 8

Mid Clinical Stage Products, H1 2012 9

Assessment by Monotherapy Products, H1 2012 11

Assessment by Route of Administration, H1 2012 12

Assessment by Stage and Route of Administration, H1 2012 13

Assessment by Molecule Type, H1 2012 14

Assessment by Stage and Molecule Type, H1 2012 15

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012